PF-Atlas › Clinical Trials › NCT01366209

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

Pirfenidone · Phase 3

Registry ID
NCT01366209
Phase
Phase 3
Status
Completed
Drug / intervention
Pirfenidone
Sponsor
Genentech, Inc.
Start
2011-06
Enrollment
555
Locations
1

About this trial

PIPF-016 (ASCEND) is a Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. The study objectives are to confirm the treatment effect of pirfenidone compared with placebo on change in percent predicted forced vital capacity (%FVC) in patients with idiopathic pulmonary fibrosis (IPF), and to confirm the safety of treatment with pirfenidone compared with placebo in patients with IPF.

View NCT01366209 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT01366209 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.